Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science

被引:46
作者
Brar, Gurmehr [1 ]
Tsukamoto, Hidekazu [1 ,2 ]
机构
[1] Univ Southern Calif, Keck Sch Med, Dept Pathol, Southern Calif Res Ctr ALPD & Cirrhosis, 1333 San Pablo St,MMR 402, Los Angeles, CA 90033 USA
[2] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA 90073 USA
关键词
Alcoholic steatohepatitis; Non-alcoholic steatohepatitis; Non-alcoholic fatty liver disease; High-fat diet; Risk factors; FATTY LIVER-DISEASE; RISK-FACTORS; AMERICAN ASSOCIATION; HEPATIC STEATOSIS; CIRCADIAN CLOCK; CONSUMPTION; PREVALENCE; DISORDERS; FIBROSIS; NONOBESE;
D O I
10.1007/s00535-018-01542-w
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
Alcohol and high-fat diet are two major risk factors responsible for metabolic diseases, which are manifested as steatohepatitis and liver cancer in the liver, and chronic pancreatitis and pancreatic adenocarcinoma (PDAC) in the pancreas. These metabolic diseases are becoming increasingly prevalent around the globe, and more importantly, their two major etiologies commonly coexist to precipitate the disease processes. To highlight the importance of these metabolic diseases, Japanese Society of Gastroenterology (JSGE) and National Institute on Alcoholism and Alcohol Abuse of National Institute of Health cosponsored the JSGE's 7th International Forum jointly held with the 12th International Symposium on ALPD and Cirrhosis. Toward the main theme of Frontiers in ASH, NASH, NBNC-HCC and PDAC, this platform showcased presentations by 12 invited international and Japanese speakers on brain-gut-liver interactions, emerging mechanisms of ASH and NASH, metabolic reprogramming, and new therapeutic targets for cirrhosis, HCC, and PDAC. This editorial discusses the most recent data on global statistics on how alcohol and obesity impact health and longevity as a prelude to a brief summary of the symposium presentations and discussions, primarily focusing on the first two session themes.
引用
收藏
页码:218 / 225
页数:8
相关论文
共 37 条
[1]
Is Moderate Alcohol Use in Nonalcoholic Fatty Liver Disease Good or Bad? A Critical Review [J].
Ajmera, Veeral H. ;
Terrault, Norah A. ;
Harrison, Stephen A. .
HEPATOLOGY, 2017, 65 (06) :2090-2099
[2]
[Anonymous], 2016, GBD COMP DAT VIS IHM
[3]
[Anonymous], 2016, AN CLASS
[4]
The Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Nonalcoholic Steatohepatitis [J].
Ascha, Mustafa S. ;
Hanouneh, Ibrahim A. ;
Lopez, Rocio ;
Tamimi, Tarek Abu-Rajab ;
Feldstein, Ariel F. ;
Zein, Nizar N. .
HEPATOLOGY, 2010, 51 (06) :1972-1978
[5]
Prevalence of and risk factors for hepatic steatosis in northern Italy [J].
Bellentani, S ;
Saccoccio, G ;
Masutti, F ;
Crocè, LS ;
Brandi, G ;
Sasso, F ;
Cristanini, G ;
Tiribelli, C .
ANNALS OF INTERNAL MEDICINE, 2000, 132 (02) :112-117
[6]
The Natural Course of Non-Alcoholic Fatty Liver Disease [J].
Bertot, Luis Calzadilla ;
Adams, Leon Anton .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (05)
[7]
Chalasani NP, 2017, HEPATOLOGY, V66, p303A
[8]
Effects of light-to-moderate alcohol consumption on steatosis and steatohepatitis in severely obese patients [J].
Cotrim, Helma P. ;
Freitas, Luiz Antonio ;
Alves, Erivaldo ;
Almeida, Alessandro ;
May, Daniel S. ;
Caldwell, Stephen .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2009, 21 (09) :969-972
[9]
Souza Mônica Rodrigues de Araújo, 2012, Arq. Gastroenterol., V49, P89, DOI 10.1590/S0004-28032012000100015
[10]
Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese [J].
Dixon, JB ;
Bhathal, PS ;
O'Brien, PE .
GASTROENTEROLOGY, 2001, 121 (01) :91-100